Potential pharmacological targets for the treatment of liver failure include miR-126a [58], and miR-126a-5p has promising potential to be developed as a new drug because it downregulates DLK1 and promotes CD4 T-cell differentiation toward Th1. Here, CD4 is linked to Hepatic failure.